Webinar: Biomarkers on the Brain: Understanding the Utility of Biomarkers for Brain Health and Disease
Learn about biomarkers, their utility in diagnosing and predicting brain disorders, and their potential to revolutionize treatment for these conditions.
Chantelle Ferland-Beckham, PhD
Director of Policy & Advocacy, Cohen Veterans Bioscience
Heather Lasseter, PhD
Associate Director, Scientific Programs, Cohen Veterans Bioscience
Biomarkers (short for biological markers) refer to a broad set of characteristics “that [can be] objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”1
In clinical practice, biomarkers are routinely used during medical examinations to monitor and predict health states. For example, a general health check may include the assessment of blood pressure, heart rate, and cholesterol as indicators a of an individual’s overall cardiovascular health. However, the use of biomarkers for brain disorders has been limited up until recently. Improvements in technology have made it easier for clinicians to reliably assess biomarkers associated with brain disorders. As a result, biomarkers are increasingly becoming instrumental in brain disorders for confirming diagnoses, choosing the best treatments, and monitoring disease progression. This translates to less invasive testing, earlier diagnosis, faster drug development, and eventually, more effective and personalized treatments.
In this webinar, we will introduce you to the concept of biomarkers, explain the different types of biomarkers that are currently being used to diagnose and predict brain disorders, and discuss the potential of biomarkers to revolutionize treatment for brain diseases.
- What are biomarkers?
- Types of biomarkers used in brain health
- Characteristics of an ideal biomarker
- Biomarkers as brain health and disease predictors
- The Need for Standardization in Measurement of Biomarkers
- The future of Biomarker-driven treatment for brain diseases
- Atkinson, Arthur & Colburn, Wayne & Degruttola, Victor & Demets, David & Downing, Gregory & Hoth, Daniel & Oates, John & Peck, Carl & Schooley, Robert & Spilker, Bert & Woodcock, Janet & Zeger, Scott. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*. Clin Pharmacol Ther. 69. 89-95.